Citations

Clear

3138 citation(s) found for "Smith, AM".

NCCN Guidelines Insights: Survivorship, Version 2.2020
Denlinger, Crystal S. , Sanft, Tara , Moslehi, Javid J. , Overholser, Linda , Demark‐Wahnefried, Wendy , Goldman, Mindy, Henry, N. Lynn , Hill‐Kayser, Christine E. , Khakpour, Nazanin , Koura, Divya, McDonough, Allison L. , Melisko, Michelle , Mooney, Kathi , Moryl, Natalie , O’Connor, Tracey L. , Patel, Chirayu G. , Peterson, Lindsay L. , Rodriguez, Maria Alma , Ruddy, Kathryn J. , Shockney, Lillie D. , Smith, Sophia K. , Syrjala, Karen L. , Zee, Phyllis C. , McMillian, Nicole R., Freedman-Cass, Deborah A., Broderick, Gregory, Henry, N Lynn , Demark-Wahnefried, Wendy , Armenian, Saro H. , Baker, Kevin Scott , Broderick, Gregory A. , Friedman, Debra L. , Hudson, Melissa M. , Moore, Halle C. F. , Paskett, Electra D. , Pirl, William F. , Tevaarwerk, Amyé

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 5, 2020 | Volume: 18 | Issue: 8 | Pages: 1016-1023

10.6004/jnccn.2020.0037 | PMID 32755975 Get It

The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for consequences of adult-onset cancer and its treatment, with the goal of helping healthcare professionals who work with survivors, including those in primary care. The guidelines also provide recommendations to help clinicians promote physical activity, weight management, and proper immunizations in survivors and facilitate care coordination to ensure that all of the survivors’ needs are addressed. These NCCN Guidelines Insights summarize additions and changes made to the guidelines in 2020 regarding cardiovascular disease risk assessment and screening for subsequent primary malignancies.
Aß 40 Mutants Protect Drosophila Against aß 42 Toxicity Despite Their Amyloidogenic Properties in the Non-transgenic Mouse Brain
Smith, M. Hamblin, Dunton, Katie L, Ceballos‐Diaz, Carolina, Jansen‐West, Karen , Dillon, Kristy, Golde, Todd E. , Levites, Yona , Mena, Lorena de , Smith, Michael, Martin, Jason Anthony , Cruz, Pedro E. , Rincón-Limas, Diego E. , Moore, Brenda D.

Mayo Clinic

No container title available | July 27, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-47473/v1 Get It

Abstract BackgroundSelf-assembly of the amyloid-β (Aβ) peptide into aggregates, ranging from small oligomers to amyloid fibrils, is fundamentally linked with Alzheimer’s disease (AD). However it is clear that not all forms of Aβ are equally harmful, and that linking a specific aggregate to toxicity also depends on the assays and model systems used [1, 2]. Indeed, though a central postulate of the amyloid cascade hypothesis, there remain many gaps in our understanding regarding the links between Aβ deposition and neurodegeneration.MethodsIn this study we utilized BRI2-Aβ fusion technology and rAAV2/1 based somatic brain transgenesis to examine Aβ aggregates that form from selective expression of individual mutant Aβ species in vivo. In parallel we generated PhiC31-based transgenic Drosophila melanogaster expressing WT and mutant Aβ40 and Aβ42, fused to the Argos signal peptide and placed under the GAL4-upstream activation sequence (UAS) expression system in order to assess the extent of Aβ42-induced toxicity as well as to interrogate the combined effect of different forms of Aβ40 and Aβ42 species.ResultsWhen expressed in the mouse brain for 6 months, Aβ42 E22G, Aβ42 E22Q/D23N, and Aβ42 WT formed amyloid aggregates consisting of some diffuse material as well as cored plaques, whereas other mutants formed predominantly diffuse amyloid deposits. Moreover, while Aβ40WT showed no distinctive phenotype, Aβ40 E22G and E22Q/D23N formed unique aggregates that accumulated in mouse brains. This is the first evidence that mutant Aβ40 overexpression leads to deposition under certain conditions. Interestingly, we found that mutant Aβ42 E22G, E22Q, and S26C, but not Aβ40, were toxic to the eye of the flies and exacerbated their behavior. In contrast, flies expressing a copy of Aβ40 (wild type [WT] or mutants) in addition to Aβ42 WT, showed improved phenotypes, suggesting possible protective qualities for Aβ40.ConclusionsThese studies suggest that some Aβ40 mutants form unique amyloid aggregates in mouse brains, despite being protective against Aβ42 toxicity in Drosophila, which highlights the significance of using different systems for a better understanding of AD pathogenicity and more accurate screening for new potential therapies.
Mitochondrial DNA: Hotspot for Potential Gene Modifiers Regulating Hypertrophic Cardiomyopathy
Kargaran, Parisa K, Evans, Jared M., Bodbin, Sara , Smith, James G.W. , Mosqueira, Diogo , Denning, Chris , Mosqueira, Diogo , Nelson, Timothy J.

Mayo Clinic

Journal of Clinical Medicine | July 23, 2020 | Volume: 9 | Issue: 8 | Pages: 2349

10.3390/jcm9082349 | PMID 32718021 Get It

Hypertrophic cardiomyopathy (HCM) is a prevalent and untreatable cardiovascular disease with a highly complex clinical and genetic causation. HCM patients bearing similar sarcomeric mutations display variable clinical outcomes, implying the involvement of gene modifiers that regulate disease progression. As individuals exhibiting mutations in mitochondrial DNA (mtDNA) present cardiac phenotypes, the mitochondrial genome is a promising candidate to harbor gene modifiers of HCM. Herein, we sequenced the mtDNA of isogenic pluripotent stem cell-cardiomyocyte models of HCM focusing on two sarcomeric mutations. This approach was extended to unrelated patient families totaling 52 cell lines. By correlating cellular and clinical phenotypes with mtDNA sequencing, potentially HCM-protective or -aggravator mtDNA variants were identified. These novel mutations were mostly located in the non-coding control region of the mtDNA and did not overlap with those of other mitochondrial diseases. Analysis of unrelated patients highlighted family-specific mtDNA variants, while others were common in particular population haplogroups. Further validation of mtDNA variants as gene modifiers is warranted but limited by the technically challenging methods of editing the mitochondrial genome. Future molecular characterization of these mtDNA variants in the context of HCM may identify novel treatments and facilitate genetic screening in cardiomyopathy patients towards more efficient treatment options.
Genetic Variation in Charcot–Marie–Tooth Genes Contributes to Sensitivity to Paclitaxel-Induced Peripheral Neuropathy
Chen, Yongzhen , Fang, Fang , Vangipuram, Kiran, Gersch, Christina L. , Rae, James M. , Hayes, Daniel F. , Henry, N. Lynn , Beutler, Andreas S. , Hertz, Daniel L. , Hertz, Daniel L , Henry, N Lynn , Kidwell, Kelley M. , Marcath, Lauren A. , Lavoie Smith, Ellen M

Mayo Clinic

Pharmacogenomics | July 23, 2020 | Volume: 21 | Issue: 12 | Pages: 841-851

10.2217/pgs-2020-0053 | PMID 32700628 Get It

Evaluation of Vasopressor Exposure and Mortality in Patients With Septic Shock*
Roberts, Russel J. , Patel, Gourang , Chen, Jen‐Ting , Phillips, Kristy M. , Lopez, Natasha , Qadir, Nida , Cairns, Charles B. , Mathews, Kusum S. , Park, Pauline, Khan, Akram , Gilmore, James F. , Brown, Anne Rain , Tsuei, Betty J., Handzel, Michele, Chang, Alfredo Lee, Herbert, James T. , Martinez, Anthony , Tonna, Joseph E. , Nazer, Lama , Heavner, Mojdeh S. , Pender, Erin, Chambers, Lauren, Kenes, Michael T. , Kaufman, David A. , Downey, April, Brown, Brent R. , Chaykosky, Darlene, Wolff, Armand, Smith, Michael , Nault, Katie, Gong, Michelle N. , Sevransky, Jonathan, Lat, Ishaq , Network, on behalf of the Observation of VariatiOn in fLUids adMinistEred in shock-CHaracterizAtion of vaSoprEssor Requirements in Shock (VOLUME-CHASERS) Study Group and SCCM Discovery, Tonna, Joseph E. , Heavner, Mojdeh S , Khan, Akram , Miano, Todd A. , Hammond, Drayton A , Kashani, Kianoush , Park, Pauline K. , Duggal, Abhijit , Lanspa, Michael J. , Ammar, Mahmoud A , Network, on behalf of the Observation of VariatiOn in fLUids adMinistEred in shock-CHaracterizAtion of vaSoprEssor Requirements in Shock (VOLUME-CHASERS) Study Group and SCCM Discovery

Mayo Clinic

Critical Care Medicine | July 22, 2020 | Volume: 48 | Issue: 10 | Pages: 1445-1453

10.1097/ccm.0000000000004476 | PMID 32706559 Get It

Objectives: The objectives of this study were to: 1) determine the association between vasopressor dosing intensity during the first 6 hours and first 24 hours after the onset of septic shock and 30-day in-hospital mortality; 2) determine whether the effect of vasopressor dosing intensity varies by fluid resuscitation volume; and 3) determine whether the effect of vasopressor dosing intensity varies by dosing titration pattern. Design: Multicenter prospective cohort study between September 2017 and February 2018. Vasopressor dosing intensity was defined as the total vasopressor dose infused across all vasopressors in norepinephrine equivalents. Setting: Thirty-three hospital sites in the United States ( n = 32) and Jordan ( n = 1). Patients: Consecutive adults requiring admission to the ICU with septic shock treated with greater than or equal to 1 vasopressor within 24 hours of shock onset. Interventions: None. Measurements and Main Results: Out of 1,639 patients screened, 616 were included. Norepinephrine (93%) was the most common vasopressor. Patients received a median of 3,400 mL (interquartile range, 1,851–5,338 mL) during the 24 hours after shock diagnosis. The median vasopressor dosing intensity during the first 24 hours of shock onset was 8.5 μg/min norepinephrine equivalents (3.4–18.1 μg/min norepinephrine equivalents). In the first 6 hours, increasing vasopressor dosing intensity was associated with increased odds ratio of 30-day in-hospital mortality, with the strength of association dependent on concomitant fluid administration. Over the entire 24 hour period, every 10 μg/min increase in vasopressor dosing intensity was associated with an increased risk of 30-day mortality (adjusted odds ratio, 1.33; 95% CI, 1.16–1.53), and this association did not vary with the amount of fluid administration. Compared to an early high/late low vasopressor dosing strategy, an early low/late high or sustained high vasopressor dosing strategy was associated with higher mortality. Conclusions: Increasing vasopressor dosing intensity during the first 24 hours after septic shock was associated with increased mortality. This association varied with the amount of early fluid administration and the timing of vasopressor titration.
Addition of an Oblique Interfragmentary Screw to T-plate Fixation Decreases Nonunion Rate in Trapeziometacarpal Arthrodesis
Pflibsen, Lacey R. , Noland, Shelley S. , Eells, Annica C. , Smith, Anthony A.

Mayo Clinic

HAND | July 22, 2020 | Volume: 17 | Issue: 3 | Pages: 447-451

10.1177/1558944720937366 | PMID 32696675 Get It

Background: T-plate fixation is a popular method for trapeziometacarpal arthrodesis in patients with osteoarthritis. Previous studies report an 8% to 18% rate of symptomatic nonunion and a 26% rate of radiographic nonunion. In this study, we present our surgical technique of trapeziometacarpal arthrodesis using the addition of an oblique interfragmentary screw to T-plate fixation on the rate of symptomatic and radiographic nonunion. Methods: A retrospective review of all trapeziometacarpal arthrodeses for osteoarthritis was completed by a single surgeon between 2010 and 2018. Preoperative demographics, pain, and Eaton classification were included. The technique was identical in all surgical cases, using a T-plate and oblique interfragmentary screw across the arthrodesis site from the metacarpal to the trapezium. Postoperative nonunion rate and time to clinical healing (absence of pain) and radiographic union were reviewed. Results: A total of 22 trapeziometacarpal arthrodeses were performed on 17 patients using the above technique. The average age was 53 years, 71% were women, and 53% involved the dominant hand. Mean preoperative Eaton classification was 2.74 (±0.73). Mean time to clinical healing was 34 days (±12 days), and mean time to radiographic union was 55 days (±23 days). Mean follow-up was 9 months, and no patients were found to have symptomatic or radiographic nonunion. Hardware removal was required bilaterally in 1 patient after complete healing. Conclusions: The addition of an oblique interfragmentary screw to T-plate fixation is a novel technique in trapeziometacarpal arthrodesis, resulting in no symptomatic or radiographic nonunion.
Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy
Nair, Dileep , Laxer, Kenneth D. , Weber, Peter, Murro, Anthony M., Park, Yong D., Barkley, Gregory L., Smith, Brien, Gwinn, Ryder P. , Doherty, Michael J. , Zimmerman, Richard S. , Bergey, Gregory K. , Anderson, William S. , Heck, Christianne, Liu, Charles Y. , Lee, Ricky W. , Sadler, Toni, Duckrow, Robert B., Wharen, Robert E. , Tatum, William O. , Srinivasan, Shraddha, Agostini, Mark, Alexopoulos, Andreas V. , Jobst, Barbara C. , Roberts, David W. , Salanova, Vicenta , Witt, Thomas C., Cash, Sydney S. , Halford, Jonathan J. , Spencer, David , Ernst, Lia , Skidmore, Christopher , Sperling, Michael R. , Miller, Ian , Geller, Eric B., Berg, Michel J., Fessler, A. James, Rutecki, Paul , Mizrahi, Eli M., Shields, Donald C. , Schwartz, Theodore H. , Labar, Douglas, Fountain, Nathan B. , Elias, W. Jeff, Olejniczak, Piotr W., Villemarette-Pittman, Nicole R. , Eisenschenk, Stephan, Roper, Steven N. , Boggs, Jane , Courtney, Tracy A., Sun, Felice T., Seale, Cairn G. , Miller, Kathy L. , Skarpaas, Tara L. , Morrell, Martha J. , Study, on behalf of the RNS System LTT, Meador, Kimford J. , Vossler, David G. , Hays, Ryan , Liow, Kore , Nair, Dileep R, Weber, Peter B, Smith, Brien J, Noe, Katherine H. , McKhann, Guy M. , Agostini, Mark A, Alexopoulos, Andreas V , Edwards, Jonathan C, Spencer, David C, Skidmore, Christopher T., Goldman, Alica M. , Gross, Robert E, Labar, Douglas R, Boggs, Jane G, Sperling, Michael R , Halford, Jonathan J , Fountain, Nathan , Meador, Kimford J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J , Ernst, Lia D , Hirsch, Lawrence J. , Cole, Andrew J. , Worrell, Gregory A. , Lundstrom, Brian N. , Edwards, Jonathan C. W. , Gross, Robert E. , Study, on behalf of the RNS System LTT

Mayo Clinic

Neurology | July 20, 2020 | Volume: 95 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000010154 | PMID 32690786 Get It

Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
Loprinzi, Charles L. , Lacchetti, Christina , Bleeker, Jonathan , Chauhan, Cynthia, Hertz, Daniel L. , Kelley, Mark R. , Lavino, Antoinette, Lustberg, Maryam B. , Schneider, Bryan P. , Smith, Mary Lou , Wagner‐Johnston, Nina D. , Hertz, Daniel L , Lustberg, Maryam , Cavaletti, Guido , Paice, Judith A. , Lavoie Smith, Ellen M , Smith, Thomas J. , Hershman, Dawn L.

Mayo Clinic

Journal of Clinical Oncology | July 14, 2020 | Volume: 38 | Issue: 28 | Pages: 3325-3348

10.1200/jco.20.01399 | PMID 32663120 Get It

PURPOSE To update the ASCO guideline on the recommended prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivors. METHODS An Expert Panel conducted targeted systematic literature reviews to identify new studies. RESULTS The search strategy identified 257 new references, which led to a full-text review of 87 manuscripts. A total of 3 systematic reviews, 2 with meta-analyses, and 28 primary trials for prevention of CIPN in addition to 14 primary trials related to treatment of established CIPN, are included in this update. RECOMMENDATIONS The identified data reconfirmed that no agents are recommended for the prevention of CIPN. The use of acetyl-l-carnitine for the prevention of CIPN in patients with cancer should be discouraged. Furthermore, clinicians should assess the appropriateness of dose delaying, dose reduction, substitutions, or stopping chemotherapy in patients who develop intolerable neuropathy and/or functional impairment. Duloxetine is the only agent that has appropriate evidence to support its use for patients with established painful CIPN. Nonetheless, the amount of benefit from duloxetine is limited. Additional information is available at www.asco.org/survivorship-guidelines .
Molecular characterization of the calcium release channel deficiency syndrome
Tester, David J. , Kim, CS John, Hamrick, Samantha K. , Ye, Dan , O’Hare, Bailey J. , Bombei, Hannah, Fitzgerald, Kristi K. , Haglund-Turnquist, Carla , Atkins, Dianne L. , Nunez, Luis A. Ochoa, Law, Ian H. , Temple, Joel , Ackerman, Michael J. , Haglund-Turnquist, Carla M, Law, Ian H

Mayo Clinic

JCI Insight | July 14, 2020 | Volume: 5 | Issue: 15 | Pages: No page available

10.1172/jci.insight.135952 | PMID 32663189 Get It

We identified a potentially novel homozygous duplication involving the promoter region and exons 1–4 of the gene encoding type 2 cardiac ryanodine receptor ( RYR2 ) that is responsible for highly penetrant, exertion-related sudden deaths/cardiac arrests in the Amish community without an overt phenotype to suggest RYR2- mediated catecholaminergic polymorphic ventricular tachycardia (CPVT). Homozygous RYR2 duplication (RYR2-DUP) induced pluripotent stem cell cardiomyocytes (iPSC-CMs) were generated from 2 unrelated patients. There was no difference in baseline Ca 2+ handling measurements between WT-iPSC-CM and RYR2-DUP-iPSC-CM lines. However, compared with WT-iPSC-CMs, both patient lines demonstrated a dramatic reduction in caffeine-stimulated and isoproterenol-stimulated (ISO-stimulated) Ca 2+ transient amplitude, suggesting RyR2 loss of function. There was a greater than 50% reduction in RYR2 transcript/RyR2 protein expression in both patient iPSC-CMs compared with WT. Delayed afterdepolarization was observed in the RYR2-DUP-iPSC-CMs but not in the WT-iPSC-CMs. Compared with WT-iPSC-CMs, there was significantly elevated arrhythmic activity in the RYR2-DUP-iPSC-CMs in response to ISO. Nadolol, propranolol, and flecainide reduced erratic activity by 8.5-fold, 6.8-fold, and 2.4-fold, respectively, from ISO challenge. Unlike the gain-of-function mechanism observed in RYR2- mediated CPVT, the homozygous multiexon duplication precipitated a dramatic reduction in RYR2 transcription and RyR2 protein translation, a loss of function in calcium handling, and a calcium-induced calcium release apparatus that is insensitive to catecholamines and caffeine.